BioWorld

Jan. 17, 2012

Record Year for Royalty Deals Builds Optimism for 2012

Not everyone is upset about the turmoil in the equity markets. Last year was a record year for the sale of royalty streams and other structured product deals, in large part because of the lack of other options for biotechs. Read More

Too Many Trials Still Published At a Glacial Pace, or Not at All

Supposedly, academia's battle cry is "publish or perish." So why are so many clinical trials going unpublished? Read More

Week in Review

Word on the Street

Week in Washington

Biotech Restructurings, Expansions, Scale-Backs, Bankruptcies: Jan. 1 - Dec. 31, 2011

Biotech Lawsuits: Jan. 1 - Dec. 31, 2011

Money Raised By Biotech In 2012 Vs. 2011

Money Raised By Biotech: Jan. 1 - 13, 2012

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...